OPXA Share Price

Open 0.66 Change Price %
High 0.69 1 Day 0.00 0.00
Low 0.66 1 Week 0.01 1.49
Close 0.68 1 Month -0.11 -13.92
Volume 20465 1 Year -1.72 -71.67
52 Week High 4.93
52 Week Low 0.50
OPXA Important Levels
Resistance 2 0.71
Resistance 1 0.70
Pivot 0.68
Support 1 0.66
Support 2 0.65
NASDAQ USA Most Active Stocks
ASTI 0.00 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
INTC 36.15 -3.42%
INTC 36.15 -3.42%
INTC 36.15 -3.42%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
More..
NASDAQ USA Top Gainers Stocks
SPIR 0.02 100.00%
LOCM 0.09 50.00%
MYRX 0.08 33.33%
STRT 32.15 30.16%
WRES 0.09 28.57%
TBBK 6.45 27.47%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
EHTH 14.18 20.78%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
LLEN 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

Opexa Therapeutics, Inc. (NASDAQ: OPXA)

OPXA Technical Analysis 5
As on 28th Apr 2017 OPXA Share Price closed @ 0.68 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 2.25 & Strong Sell for SHORT-TERM with Stoploss of 0.85 we also expect STOCK to react on Following IMPORTANT LEVELS.
OPXA Target for May
1st Target up-side 0.78
2nd Target up-side 0.85
3rd Target up-side 0.92
1st Target down-side 0.58
2nd Target down-side 0.51
3rd Target down-side 0.44
OPXA Other Details
Segment EQ
Market Capital 14797129.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.opexatherapeutics.com
OPXA Address
OPXA
2635 Technology Forest Boulevard
The Woodlands, TX 77381
United States
Phone: 281-272-9331
Fax: 281-872-8585
OPXA Latest News
Interactive Technical Analysis Chart Opexa Therapeutics, Inc. ( OPXA NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Opexa Therapeutics, Inc.
OPXA Business Profile
Opexa Therapeutics, Inc. (Opexa) is a biopharmaceutical company. The Company is engaged in developing personalized cellular therapies with the potential to treat illnesses, including multiple sclerosis (MS). These therapies are based on its T-cell technology. The Company�s core product candidate, Tovaxin, is a personalized T-cell therapeutic vaccine licensed from Baylor College of Medicine, which is in clinical development for the treatment of MS. Tcelna is a T-cell immunotherapy in Phase IIb clinical development for the treatment of patients with secondary progressive MS (SPMS).Tcelna is a personalized therapy that is specifically tailored to each patient�s disease profile. The TERMS study was a multi-center, randomized, double blind, placebo-controlled trial in 150 patients with RRMS or high risk Clinically Isolated Syndrome.